Ethinyl estradiol / etonogestrel Vaginal System [NuvaRing]
RxNorm 2201660

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2201660 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ethinyl estradiol / etonogestrel Vaginal System [NuvaRing].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDF
Ethinyl estradiol / etonogestrel Vaginal System [NuvaRing]
AUI:12316105
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDFPrescribable

Semantic Branded Drug Form (SBDF):
Ethinyl estradiol / etonogestrel Vaginal System [NuvaRing]
(Atom ID: 12316105)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
ethinyl estradiol / etonogestrel Vaginal System [NuvaRing]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2201660
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12316105
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDF
Semantic Branded Drug Form (Ingredient + Dose Form + Brand Name)
Source Code
2201660
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Estrogen and Progestin (Vaginal Ring Contraceptives)


Estrogen and progestin vaginal ring contraceptives are used to prevent pregnancy. Estrogen (ethinyl estradiol) and progestin (etonogestrel or segesterone) are two female sex hormones. Estrogen and progestin are in a class of medications called combination hormonal contraceptives (birth control medications). Combinations of estrogen and progestin work by preventing ovulation (the release of eggs from the ovaries). They also change the lining of the uterus (womb) to prevent pregnancy from developing and change the mucus at the cervix (opening of the uterus) to prevent sperm (male reproductive cells) from entering. Contraceptive vaginal rings are a very effective method of birth control, but they do not prevent the spread of human immunodeficiency virus (HIV, the virus that causes acquired immunodeficiency syndrome [AIDS]) and other sexually transmitted diseases.
[Learn More]


* Please review the disclaimer below.